Pharma Focus Asia

Avenge Bio Introduced AVB-001, a Novel Cell Therapy

Avenge Bio has introduced AVB-001, a novel cell therapy leveraging the LOCOcyte™ immunotherapy platform.

AVB-001 is specifically designed for treating patients facing the challenges of relapsed resistant/refractory ovarian cancer. 

In a pioneering first-in-human phase 1/2 multicenter study (NCT05538624), the safety and effectiveness of AVB-001 are under evaluation. AVB-001 is an encapsulated cell product engineered to produce native human interleukin-2 (hIL-2), administered intraperitoneally (IP) to patients.

The LOCOcyte™ allogeneic cell-based immunotherapy platform offers the unique advantage of potent localised immune system modulation, leading to a systemic immune response that can address previously untreatable cancers. This technology capitalises on three distinct benefits:

  • Synthetically engineered allogeneic cells generate powerful immune effector molecules, providing a readily available therapy 

  • The therapy is localised near the primary tumour site, stimulating both innate and adaptive immune responses 

  • The immunomodulator trains the patient's immune system to mount a robust response, targeting and eliminating distant metastases without causing systemic toxicity.


Avenge Bio has been granted FDA fast track designation for AVB-001, an innovative cell therapy harnessing the power of the LOCOcyte™ immunotherapy platform.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Advanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024